Literature DB >> 12459620

Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.

Heidi W Shappell1, Maureen A Riopel, Ann E Smith Sehdev, Brigitte M Ronnett, Robert J Kurman.   

Abstract

Ovarian endocervical-type (müllerian) mucinous tumors and tumors composed of a mixture of endocervical-type mucinous, serous, endometrioid, squamous, and indifferent cells with abundant eosinophilic cytoplasm reported to date have been primarily limited to borderline and microinvasive types, with only one report of a disease-related death. The clinicopathologic features of 54 endocervical-type and mixed cell-type mucinous tumors, defined as tumors with papillary architecture resembling serous tumors but containing endocervical-type mucinous epithelium, were evaluated. Thirty-four tumors (64%) were classified as atypical proliferative (borderline) tumors based on the absence of stromal invasion and the absence of micropapillary architecture measuring >5 mm. Five tumors (9%) qualified as intraepithelial carcinoma based on the presence of marked cytologic atypia or a complex cribriform growth pattern involving the epithelium covering the surface of papillae or lining cystic spaces. Eight tumors (15%) with stromal invasion < or =5 mm were classified as microinvasive carcinoma. Seven tumors (13%) with either stromal invasion (five tumors) or micropapillary architecture measuring >5 mm (two tumors) were classified as carcinoma. Sixteen tumors (30%) were bilateral, and endosalpingiosis was identified in 41% of cases. Serous-type differentiation was present in all cases. Of the 29 patients with atypical proliferative tumors, intraepithelial carcinomas, and microinvasive carcinomas for whom follow-up was available, there were no disease-related deaths. In contrast, of the seven patients whose tumors had either stromal invasion or micropapillary architecture >5 mm, two stage III patients died of disease (one with frank invasion and one with a micropapillary tumor that lacked stromal invasion). One other stage III patient with a noninvasive micropapillary carcinoma was alive with disease at 84 months. The remaining four patients (three stage I and one stage III) were alive with no evidence of disease. In summary, most endocervical-type atypical proliferative tumors are stage I and benign. The presence of either intraepithelial carcinoma or microinvasion has no adverse effect on behavior. Rare endocervical-type mucinous tumors demonstrate histologically malignant features and aggressive behavior that warrant designation as carcinoma. As with serous tumors, micropapillary architecture without frank invasion in endocervical-type mucinous tumors is associated with disease recurrence and death when presenting as advanced-stage disease. All the tumors in this study were composed of a heterogeneous population of cells, consisting mainly of serous (ciliated) and endocervical-type mucinous cells. In addition, they all contained endometrioid-type cells, hobnail cells, and indifferent cells with abundant eosinophilic cytoplasm to a varying degree. Accordingly, it appears that tumors that feature endocervical-type mucinous cells are rarely if ever pure but almost invariably of mixed cell type. Despite containing mucinous epithelium, the papillary architecture, serous-type differentiation, association with endosalpingiosis, frequent bilaterality, size, and clinical behavior of endocervical-type mucinous tumors closely resemble serous tumors. We therefore recommend the term "seromucinous" for these tumors, which acknowledges both their serous and mucinous features.

Entities:  

Mesh:

Year:  2002        PMID: 12459620     DOI: 10.1097/00000478-200212000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  26 in total

1.  Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors.

Authors:  Taira Hada; Morikazu Miyamoto; Hiroki Ishibashi; Haruka Kawauchi; Hiroaki Soyama; Hiroko Matsuura; Takahiro Sakamoto; Soichiro Kakimoto; Tadashi Aoyama; Hideki Iwahashi; Rie Suzuki; Hitoshi Tsuda; Masashi Takano
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Adhering to the 2014 WHO terminology on borderline ovarian tumors.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2017-02       Impact factor: 4.064

Review 3.  [Pitfalls and common problems in the differential diagnosis of epithelial ovarian tumors].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

Review 4.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

Review 5.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

Review 6.  Epithelial borderline ovarian tumor: Diagnosis and treatment strategy.

Authors:  Kimio Ushijima; Kouichiro Kawano; Naotake Tsuda; Shin Nishio; Atsumu Terada; Hiroyuki Kato; Kazuto Tasaki; Ken Matsukuma
Journal:  Obstet Gynecol Sci       Date:  2015-05-19

Review 7.  Mucinous tumors of the ovary: current thoughts on diagnosis and management.

Authors:  Jubilee Brown; Michael Frumovitz
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

8.  Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.

Authors:  M Polat; T Senol; E Ozkaya; G Ogurlu Pakay; M S Cikman; B Konukcu; M A Ozten; A Karateke
Journal:  Clin Transl Oncol       Date:  2015-08-20       Impact factor: 3.405

Review 9.  [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].

Authors:  S Lax; A Staebler
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

Review 10.  Seromucinous Tumors of the Ovary. What's in a Name?

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2016-01       Impact factor: 2.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.